InflaRx (NASDAQ: IFRX) had its price target raised by analysts at Guggenheim from $7.00 to $10.00. They now have a "buy" rating on the stock.
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting [Yahoo! Finance]